NICOLAS DEJONG: Open Payments
NPI 1902204803 · OXNARD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$612 in 29 payments from 8 companies in 2025. Trend: 2023 $257 · 2024 $379 · 2025 $612
Food & beverage: $612
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 12 | $227 |
| AstraZeneca Pharmaceuticals LP | 8 | $163 |
| Lilly USA, LLC | 2 | $55 |
| Amgen Inc. | 2 | $48 |
| GlaxoSmithKline, LLC. | 2 | $37 |
| Optinose US, Inc. | 1 | $29 |
| ABIOMED | 1 | $29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $24 |
Products named: Ozempic, AIRSUPRA, MOUNJARO, Wegovy, OTEZLA, TRELEGY ELLIPTA, FARXIGA, Xhance.
Industry payments across CA — which companies pay providers there.
